FDA removes positive test requirement for two COVID-19 outpatient therapies
The Food and Drug Administration last week removed the requirement for a positive COVID-19 test result to prescribe Paxlovid to certain adult and pediatric patients and Lagevrio to certain adults at risk of progressing to severe COVID-19. The agency continues to recommend that health care providers use direct SARS-CoV-2 viral testing to help diagnose COVID-19, but said it recognizes that providers may in rare instances diagnose COVID-19 in patients with a negative test result but symptoms and a recent known exposure to COVID-19. For more information, see the updated Paxlovid and Lagevrio fact sheets for health care providers.
Related News Articles
Headline
Most health insurers must cover the updated COVID-19 vaccines from Pfizer and Moderna without cost sharing effective Sept. 11, when the Food and Drug…
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…
Headline
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and…
Headline
Receiving a COVID-19 mRNA vaccine or booster during pregnancy can benefit pregnant people and their newborn infants, according to findings from a federally…